NuVasive Announces Preliminary Unaudited Full Year 2008 Financi... ( Anticipates Full Year 2008 Revenue of...)

NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results

Date:1/23/2009

Anticipates Full Year 2008 Revenue of Approximately $250 Million

Announces Full Year 2009 Revenue Guidance of $345 Million to $350 Million

SAN DIEGO, Jan. 23 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, today announced preliminary unaudited financial results for the full year ended December 31, 2008 and provided financial guidance for the full year 2009.

NuVasive anticipates full year 2008 revenue of approximately $250 million. The Company also expects to exceed its Osteocel(R) guidance for 2008 with $10 million in revenue and is now launching the product through its exclusive sales force. The Company announced anticipated full year 2008 revenue in advance of its National Sales Meeting, which will take place January 23-24, 2009. The Company anticipates full year 2008 earnings per share of $0.07 - $0.09 excluding in-process research and development costs and other adjustments related to a one-time leasehold termination charge, transitional support costs related to the Company's ERP system, and intellectual property litigation expense.

NuVasive also announced revenue guidance for the full year 2009. The Company expects full year 2009 revenue to be in the range of $345 million to $350 million. Osteocel revenue in the fourth quarter 2008 included approximately $5 million in sales to former distributors of Osiris Therapeutics, Inc. (Nasdaq: OSIR). As the Company launches the Osteocel product through its exclusive sales force, it will not have the benefit of this revenue in first quarter 2009. As a result, overall first quarter 2009 revenue should be flat compared to fourth quarte
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference
2. NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference
3. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
4. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
5. NuVasive Acquires First Stem Cell Bone Graft Substitute
6. NuVasive Reports First Quarter 2008 Financial Results
7. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
8. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
9. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
10. NuVasive to Present at BIOCOM Investor Conference 2007
11. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires

Post Your Comments:

(Date:11/25/2009)...toid arthritis, could help newly diagnosed diabeti...HealthDay News) -- A drug commonly used to treat n... also shows some promise in helping patients newly...tuximab (Rituxan), helped patients keep producing ... had destroyed some of their pancreatic beta cells...

(Date:11/25/2009)...ns of trouble with the H1N1 vaccine, , ,...ng H1N1 swine flu pandemic may be driving a recent...nts, a U.S. health official said Wednesday. , "...infections around the country," Dr. Anne Schuchat,...and Respiratory Diseases at the U.S. Centers for D...

(Date:11/25/2009)...carried into the body on a carefully engineered, f...ly eliminate tumors in mammals, scientists report ...dicine . , The new approach, pioneered by bioeng...es plastic disks impregnated with tumor-specific a...the mammalian immune system to attack tumors. The ...

(Date:11/25/2009)...mimicked parts of speech colored perception of sou...ws) -- People can "hear" not only with their ears,..., In fact, sensations on the skin designed to mimi...ecipher sounds better, the Canadian scientists fou...we could use tactile information in this way," sai...

(Date:11/25/2009)...rstCall/--TheAdvisoryBoardCompany(Nasdaq: ABCO )an...perJaffrayHealthCareConferenceinNewYorkCity.Speaki...llbetheCompany,sChiefExecutiveOfficer,RobertW.Muss...elT.Kirshbaum.Thepresentationmaterialswillbeavaila...ryboardcompany.com ,throughDecember16,2009. ,, ...

Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2 Health News:Type 1 Diabetes May Have a New Foe 3 Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2 Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3 Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4 Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2 Health News:Your Skin Can Help Your Ears Listen 2 Health News:Your Skin Can Help Your Ears Listen 3

[0] Type 1 Diabetes May Have a New Foe [0] Swine Flu Tied to Rise in Pneumonias Among Young [1] Implant-based cancer vaccine is first to eliminate tumors in mice [0] Your Skin Can Help Your Ears Listen [0] The Advisory Board Company to Present at 21st Annual Piper Jaffray Health Care Conference

...Share Repurchase Authorization -, BRAINTREE, Mass...day reported fourth quarter fiscal 2008 GAAP net,r...of $20 million, down,21%; and net earnings per sha...2%, and net earnings per share of,$1.94, up 9%., ...

...hting Key Histology Findings to Be Included ...INDIANAPOLIS, May 1 Eli Lilly and Company,will un...nual Meeting of,the American Society of Clinical O...ion), GEMZAR(R) (gemcitabine HCl for,injection), a...

...ongenital heart disease are receiving implantable ...per heart rhythm. ICDs were first introduced for a...well they work in children, who account for less t...e. It finds the devices to be life-saving, but als...

...ng a different kind of high -- approximately seven... to 12) report participating in a thrill-seeking a...lf-asphyxiation or having been choked by someone e...gical health of Ontarios youth, in the Mental Heal...

...a major step toward a practical energy source for ...izona report development of a new generation of su...ore powerful than existing motors. Their study is ...luding so-called catalytic nanomotors, are made wi...

...troke key factors in progression toward dementia ,...ression in women and stroke in men are critical fa...rench researchers report. , They analyzed data fro...start of the study. , They were assessed two and f...

Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009 Lilly Oncology to Unveil More Than 50 Studies at ASCO 2008 Largest study to date finds benefits of ICDs in children The 'choking game,' psychological distress and bullying Go Speed Racer! Revving up the world's fastest nanomotors Alzheimer's Disease Risk Factors May Be Gender-Specific

(Date:11/24/2009)... ,, PITTSBURGH,Nov.24/PRNewswire/-- ,, WH...r23yearsfollowinganautoaccident,wasactuallyfullyco...odMorningAmericasegment.TheDynaVoxEyeMaxwasfeature...dromeandotherconditionscanunlockcommunication. ,...ailableonlineat www.dynavoxtech.com ,, W...

(Date:11/24/2009)... ,, SANDIEGO,Nov.24/PRNewswire-FirstCall/--A...odaythatitwillpresentatthe21stAnnualPiperJaffrayHe...m.EST(6:00a.m.PST).TheconferenceisbeingheldatTheNe...iefExecutiveOfficerofAnadys,willprovideanoverviewo...ANA773. ,, Thecorporatepresentationwillbesimult...

(Date:11/24/2009)... ,, SANDIEGO,Nov.24/PRNewswire/--Accumetrics...fyNow®System,thefirstrapidandeasy-to-usediagn...tipleantiplateletagents(e.g.Plavix®andaspirin...ofAccumetrics,andGregoryJ.Tibbitts,ChiefFinancialO...viewatthe21stAnnualPiperJaffrayHealthCareConferenc...

Breaking Medicine Technology:DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2 Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2 Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2 Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 1 Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 2 Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 3 Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 4 Sound Surgical Technologies Chief Technology Officer Presents Paper on Focused Ultrasound Technology 47724 1 Sound Surgical Technologies Chief Technology Officer Presents Paper on Focused Ultrasound Technology 47724 2 China Sky One Medical Inc Obtains SFDA Approval for Diclofenac Sodium Eye Drops 47721 1 China Sky One Medical Inc Obtains SFDA Approval for Diclofenac Sodium Eye Drops 47721 2 China Sky One Medical Inc Obtains SFDA Approval for Diclofenac Sodium Eye Drops 47721 3

[0] DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years [0] Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference [0] Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference

...ial Expected to Initiate in 2010 for Blinatumomab ... MITI ), a biopharmaceutical company developing no...ancer, inflammation and autoimmune diseases, today...nalysts at The Yale Club of New York City. , , ... development across Micromet,s BiTE antibody platf...

... Presented Today at 44th Annual Meeting of EASL , ... Status During Q1 Financial Results Call at 5 P.M....aceuticals, Inc. (Nasdaq: ANDS ) today announced...cleoside polymerase inhibitor, demonstrated potent...l tolerated in a Phase Ib study in which patients ...

Other Medicine Technology:Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2 Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3 Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4 ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 2 ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 3 ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 4 ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 5 ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 6 ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 7 ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 8

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

Pure Eyes

Graether Collar Button

Lobob Hard Lens Soaking Solutions

Crawford Fascia Stripper

Medicine Products:

Pure Eyes Graether Collar Button Lobob Hard Lens Soaking Solutions Crawford Fascia Stripper

NuVasive Announces Preliminary Unaudited Full Year 2008 Financi...( Anticipates Full Year 2008 Revenue of...),Health